Filtered By:
Source: Clinical Breast Cancer
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 65 results found since Jan 2013.
Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
CONCLUSION: The risk score model was effective for predicting both prognosis and sensitivity to therapeutic drugs, suggesting its possible usefulness for the management of patients with breast cancer.PMID:37736788 | DOI:10.1007/s00432-023-05372-z
Source: Clinical Breast Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Shuyan Liu Yiwen Zheng Shujin Li Yaoqiang Du Xiaozhen Liu Hongchao Tang Xuli Meng Qinghui Zheng Source Type: research
Identification of a TRP channel-related risk model for predicting prognosis and therapeutic effects of patients with hepatocellular carcinoma
CONCLUSIONS: We successfully established a highly accurate prognostic model for predicting overall survival and therapeutic effects using TRP channel-related genes.PMID:37733242 | DOI:10.1007/s00432-023-05394-7
Source: Clinical Breast Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Chong Pang Zhe Xu Jilong Han Fujun Li Hongyan Zhu Jiaqi Zhang Dong Wang Xundi Xu Source Type: research
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
CONCLUSIONS: High immune features predict docetaxel response, and high DDR signature scores predict carboplatin response in treatment-naïve mTNBC. Integrating multimodal DDR and immune-related markers identifies subgroups with differential treatment sensitivity. Treatment options for patients with immune-low and DDR-proficient tumors remains an outstanding need. Caution is needed using PT-derived transcriptional signatures to direct treatment in mTNBC, particularly DDR-related markers following prior chemotherapy.PMID:37574209 | DOI:10.1158/1078-0432.CCR-23-0370
Source: Clinical Breast Cancer - August 13, 2023 Category: Cancer & Oncology Authors: Holly Tovey Orsolya Sipos Joel S Parker Katherine A Hoadley Jelmar Quist Sarah Kernaghan Lucy Kilburn Roberto Salgado Sherene Loi Richard D Kennedy Ioannis Roxanis Patrycja Gazinska Sarah E Pinder Judith Bliss Charles M Perou Syed Haider Anita Grigoriadis Source Type: research
Characterization of tumor microenvironment infiltration and therapeutic responses of cell cycle-related genes' signature in breast cancer
CONCLUSION: The nomogram based on CCG could assess tumour immune micro-environment regulation and therapeutic responses of immunotherapy in BC. Moreover, it may provide novel information on the control of immune micro-environment infiltration in BC and aid in the development of targeted immunotherapy.PMID:37540256 | DOI:10.1007/s00432-023-05198-9
Source: Clinical Breast Cancer - August 4, 2023 Category: Cancer & Oncology Authors: Huacong Wu Yutao Chen Mengyi Li Zijun Chen Jie Liu Guie Lai Source Type: research
Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
CONCLUSION: This study reports real-world evidence showing similar pCR and EFS outcomes with treatment regimens with and without AC and raises awareness of possible overtreatment and long-term toxicity in some patients with HER2+ EBC with the use of AC.PMID:37479867 | DOI:10.1007/s40261-023-01291-6
Source: Clinical Breast Cancer - July 21, 2023 Category: Cancer & Oncology Authors: In ês Soares de Pinho Paulo Luz Lucy Alves Raquel Lopes-Br ás Vanessa Patel Miguel Esperan ça-Martins Lisa Gon çalves Ritas Freitas Diana Sim ão Maria Rold án Galnares Isabel Fernandes Silvia Artacho Criado Salvador Gamez Casado Jose Baena Ca ñada Source Type: research
Simultaneously metastatic cholangiocarcinoma and small intestine cancer from breast cancer misdiagnosed as primary cholangiocarcinoma: A case report
CONCLUSION: Simultaneous metastatic cholangiocarcinoma and small intestine cancer from breast cancer are rare and the prognosis is extremely poor. Improving preoperative diagnostic accuracy is beneficial to avoid excessive surgical treatment. Treatment should be aimed at relieving biliary obstruction and abdominal pain, and then supplemented with chemotherapy and targeted therapy to control tumor progression and prolong the patient's life.PMID:37449239 | PMC:PMC10336993 | DOI:10.12998/wjcc.v11.i18.4446
Source: Clinical Breast Cancer - July 14, 2023 Category: Cancer & Oncology Authors: Xin Jiao Mi-Mi Zhai Fang-Zhou Xing Xiao-Ling Wang Source Type: research
Aminosteroid RM-581 Decreases Cell Proliferation of All Breast Cancer Molecular Subtypes, Alone and in Combination with Breast Cancer Treatments
This study demonstrates that RM-581 could be effective for the treatment of BC, especially TNBC.PMID:37445276 | DOI:10.3390/jcm12134241
Source: Clinical Breast Cancer - July 14, 2023 Category: Cancer & Oncology Authors: Anna Burguin Jenny Roy Genevi ève Ouellette Ren é Maltais Juliette Bherer Caroline Diorio Donald Poirier Francine Durocher Source Type: research
Simultaneously metastatic cholangiocarcinoma and small intestine cancer from breast cancer misdiagnosed as primary cholangiocarcinoma: A case report
CONCLUSION: Simultaneous metastatic cholangiocarcinoma and small intestine cancer from breast cancer are rare and the prognosis is extremely poor. Improving preoperative diagnostic accuracy is beneficial to avoid excessive surgical treatment. Treatment should be aimed at relieving biliary obstruction and abdominal pain, and then supplemented with chemotherapy and targeted therapy to control tumor progression and prolong the patient's life.PMID:37449239 | PMC:PMC10336993 | DOI:10.12998/wjcc.v11.i18.4446
Source: Clinical Breast Cancer - July 14, 2023 Category: Cancer & Oncology Authors: Xin Jiao Mi-Mi Zhai Fang-Zhou Xing Xiao-Ling Wang Source Type: research
Aminosteroid RM-581 Decreases Cell Proliferation of All Breast Cancer Molecular Subtypes, Alone and in Combination with Breast Cancer Treatments
This study demonstrates that RM-581 could be effective for the treatment of BC, especially TNBC.PMID:37445276 | DOI:10.3390/jcm12134241
Source: Clinical Breast Cancer - July 14, 2023 Category: Cancer & Oncology Authors: Anna Burguin Jenny Roy Genevi ève Ouellette Ren é Maltais Juliette Bherer Caroline Diorio Donald Poirier Francine Durocher Source Type: research
Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients
CONCLUSIONS: According to our analysis, the risk factors obesity and prevalence of CTCs are not associated and may represent independent prognostic factors.PMID:37336651 | DOI:10.1016/j.clbc.2023.05.011
Source: Clinical Breast Cancer - June 19, 2023 Category: Cancer & Oncology Authors: Marie Tzschaschel Thomas W P Friedl Fabienne Schochter Sabine Sch ütze Arkadius Polasik Tanja Fehm Klaus Pantel Christian Schindlbeck Andreas Schneeweiss J örg Schreier Hans Tesch Ralf Lorenz Viktoria Aivazova-Fuchs Lothar H äberle Peter Fasching Wolfg Source Type: research
Adjuvant Chemotherapy in Older Women With Early Breast Cancer
J Clin Oncol. 2023 Jan 30:JCO2202477. doi: 10.1200/JCO.22.02477. Online ahead of print.ABSTRACTThe Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.The clinical disc...
Source: Clinical Breast Cancer - January 30, 2023 Category: Cancer & Oncology Authors: Dario Trapani Source Type: research
Risk factors for taxane-induced peripheral neuropathy in patients with breast cancer
CONCLUSION: Cumulative dose, BMI, BSA, and hypocalcemia are all risk factors for overall TIPN, whereas cumulative dose and BSA are risk factors for moderate-severe TIPN. Patients with breast cancer who have high BMI, large BSA, hypocalcemia, and large cumulative dose may be at risk of TIPN, and intervention measures must be actively carried out for them.PMID:36658674 | DOI:10.1111/ajco.13923
Source: Clinical Breast Cancer - January 19, 2023 Category: Cancer & Oncology Authors: Cuilv Liang Yin Zhang Qi Ying Chen Wen Fa Chen Ming Zhu Chen Source Type: research
